Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer
ConditionNon Small Cell Lung Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age19+
SponsorSTCube, Inc.
About this trial
A Multicenter, Phase 2 Clinical Trial Based on an Adaptive Design to Evaluate the Safety and Efficacy of Nelmastobart in Combination with Docetaxel in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer Who Are Resistant or Intolerant to Platinum-based Chemotherapy and/or Immunotherapy
Eligibility criteria
Qualifiers
Histologically or cytologically confirmed stage IIIb, IIIc, or IV 4 recurrent non-squamous NSCLC
BTN1A1 TPS score ≥50
Subjects with positive AGA must have progressed after At least 1 platinum-based chemotherapy and/or immunotherapy AND at least 1 locally approved targeted therapy appropriate to the AGA
Subjects with negative AGA must have progressed after prior PD1/ (PDL therapy and/or platinum-based chemotherapy
Disqualifiers
Known hypersensitivity to the active ingredients or excipients of the study drug.
History of using Docetaxel for palliative therapy.
Prior treatment with Cytotoxic chemotherapy or oral targeted therapy within 14 days.
Investigational drugs within 5 half-lives.
Trial design
Treatments tested in this trial
- Nelmastobart and Docetaxel
Treatment groups
62 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov